IBIO, INC. Payments to Acquire Debt Securities, Available-for-sale
IBIO, INC. (IBIO) reported Payments to Acquire Debt Securities, Available-for-sale of $42.30 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-28
- IBIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $9.87M.
- IBIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $8.50M.
- IBIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $2.47M.
- IBIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $21.46M.
- IBIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2026 was $42.30M.
- IBIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $6.84M, a 27.68% increase from fiscal 2022.
- IBIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $5.36M, a 77.52% decline from fiscal 2021.
- IBIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2021 was $23.82M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-28 | $18.37M derived: sum of 2 quarters · filed 2026-08-28 | $20.84M derived: sum of 3 quarters · filed 2026-08-28 | $42.30M 10-K · filed 2026-08-28 |
| 2026-03-31 | $8.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-12 | $10.97M derived: sum of 2 quarters · filed 2026-05-12 | $32.43M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $2.47M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-02-10 | $23.93M 10-Q · filed 2026-02-10 | ||
| 2025-09-30 | $21.46M 10-Q/A · filed 2025-11-17 | |||
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-02-10 | $0.00 10-Q · filed 2026-02-10 | ||
| 2024-09-30 | $0.00 10-Q/A · filed 2025-11-17 | |||
| 2023-06-30 | $6.84M 10-K/A · filed 2024-09-24 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-09-27 | $1.02M derived: sum of 3 quarters · filed 2023-09-27 | $2.97M derived: sum of 4 quarters · filed 2023-09-27 |
| 2022-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-27 | $1.02M derived: sum of 2 quarters · filed 2023-09-27 | $2.97M derived: sum of 3 quarters · filed 2023-09-27 | $5.36M 10-K · filed 2023-09-27 |
| 2022-03-31 | $1.02M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-05-15 | $2.97M derived: sum of 2 quarters · filed 2023-05-19 | $5.36M 10-Q · filed 2023-05-15 | $8.21M derived: sum of 4 quarters · filed 2023-05-19 |
| 2021-12-31 | $1.95M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-05-19 | $4.34M 10-Q/A · filed 2023-05-19 | $7.19M derived: sum of 3 quarters · filed 2023-05-19 | $11.69M derived: sum of 4 quarters · filed 2023-05-19 |
| 2021-09-30 | $2.39M 10-Q · filed 2022-11-14 | $5.24M derived: sum of 2 quarters · filed 2022-11-14 | $9.74M derived: sum of 3 quarters · filed 2022-11-14 | $20.18M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-11 | $7.35M derived: sum of 2 quarters · filed 2022-10-11 | $17.80M derived: sum of 3 quarters · filed 2022-10-11 | $23.82M 10-K · filed 2022-10-11 |
| 2021-03-31 | $4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-12 | $14.95M derived: sum of 2 quarters · filed 2022-05-12 | $20.96M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $10.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $16.47M 10-Q · filed 2022-02-14 | ||
| 2020-09-30 | $6.02M 10-Q · filed 2021-11-15 | |||
| 2019-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-16 | $0.00 10-Q · filed 2021-02-16 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |